Novartis AG (NVSEF) Capital expenditures 2016–2025
Novartis AG (NVSEF) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$1.5BFY2025 · since FY2016: $1.9B → $1.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.5B | +13.3% |
| FY2024 | $1.4B | +28.9% |
| FY2023 | $1.1B | +15.7% |
| FY2022 | $916.0M | -14.1% |
| FY2021 | $1.1B | -16.4% |
| FY2020 | $1.3B | -7.5% |
| FY2019 | $1.4B | +10.0% |
| FY2018 | $1.3B | -5.4% |
| FY2017 | $1.3B | -28.8% |
| FY2016 | $1.9B | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice